Ostatní
Návod 
Halozyme Therapeutics, Inc.
HALO
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
8.1B
Obrat
1B
Zisk
0B
Aktiva
2B
Dluh
2B
ROE
0%
ROA
0%
PE
24
PS
5
Cena 1R
48-80
⌀ Cena
64.08
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
17-02-2026
Poslední dividenda
Profil
Společnost Halozyme Therapeutics, Inc. působí jako společnost využívající biofarmaceutické technologie ve Spojených státech, Švýcarsku, Irsku, Belgii, Japonsku a na mezinárodní úrovni. Výrobky společnosti jsou založeny na technologii ENHANZE pro aplikaci léčiv, patentovaném rekombinantním enzymu lidské hyaluronidázy (rHuPH20), který umožňuje subkutánní aplikaci injekčně aplikovatelných biologických látek, jako jsou monoklonální protilátky a jiné terapeutické molekuly, stejně jako malé molekuly a tekutiny. Jeho stěžejním produktem je Hylenex recombinant, léková forma rHuPH20 pro usnadnění subkutánního podávání tekutin za účelem dosažení hydratace pro zvýšení disperze a absorpce dalších injekčně podávaných léků v subkutánní urografii a pro zlepšení resorpce radiopatických látek. Společnost vyvíjí také přípravky Perjeta; RITUXAN HYCELA a MabThera SC pro léčbu nehodgkinských lymfomů a chronické lymfatické leukémie (CLL); RITUXAN SC pro pacienty s CLL a HYQVIA pro léčbu poruch imunodeficience. Dále vyvíjí přípravek Tecentriq pro nemalobuněčný karcinom plic; OCREVUS pro roztroušenou sklerózu; DARZALEX pro léčbu pacientů s amyloidózou, doutnajícím myelomem a mnohočetným myelomem; nivolumab pro léčbu solidních nádorů; ARGX- 113, lidský novorozenecký Fc receptor; ARGX- 117 pro léčbu autoimunitních onemocnění; a BMS- 986179, protilátka proti CD- 73. Společnost spolupracuje s F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Program of Research in South Africa a ViiV Healthcare Limited pro malé a velké molekulární cíle pro léčbu a prevenci HIV. Společnost Halozyme Therapeutics, Inc. byla založena v roce 1998 a sídlí v kalifornském San Diegu.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
350
Založení
2004-03-16
Podobné společnosti
$ 72.96
- $ 0.76
$ 96.93
- $ 3.37
$ 61.81
+ $ 1.65
$ 95.23
- $ 0.01
$ 132.79
+ $ 1.63
$ 8.52
+ $ 0.08
$ 72.15
+ $ 0.25
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 1,396.6 | 1,396.6 | 1,015.3 | 829.3 | 660.1 | 443.3 | 267.6 | 196.0 | 151.9 | 316.6 | 146.7 | 135.1 | 75.3 | 54.8 | 42.3 | 56.1 | 13.6 | |
| Cost of Revenues | 252.2 | 305.4 | 159.4 | 192.4 | 139.3 | 81.4 | 43.4 | 45.5 | 10.1 | 31.2 | 33.2 | 29.2 | 22.7 | 6.2 | 1.1 | 0.3 | 1.0 | |
| Gross Profit | 1,144.5 | 1,091.2 | 855.9 | 636.9 | 520.8 | 361.9 | 224.2 | 150.4 | 141.7 | 285.5 | 113.5 | 105.8 | 52.6 | 48.6 | 41.2 | 55.8 | 12.6 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 451.8 | 354.3 | 325.7 | 264.9 | 298.0 | 290.1 | 231.4 | 195.9 | 230.0 | 216.0 | |
| Cost of Revenues | 102.1 | 55.2 | 46.4 | 48.4 | 42.1 | 49.4 | 57.4 | 46.1 | 52.3 | 54.8 | |
| Gross Profit | 349.6 | 299.0 | 279.4 | 216.5 | 256.0 | 240.7 | 174.0 | 149.8 | 177.7 | 161.2 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 76.4 | 66.6 | 35.7 | 34.2 | 140.8 | 150.3 | 150.6 | 150.8 | 93.2 | 79.7 | 96.6 | 70.0 | 57.6 | 51.8 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 149.2 | 143.5 | 50.3 | 45.7 | 77.3 | 60.8 | 53.8 | 45.9 | 40.0 | 35.9 | 32.3 | 24.8 | 18.1 | 15.1 | |
| Depreciation & Amortization | 129.0 | 88.1 | 81.3 | 84.9 | 43.1 | 3.0 | 3.3 | 4.1 | 2.4 | 2.2 | 2.4 | 1.7 | 1.8 | 1.2 | 1.1 | 1.1 | 1.5 | |
| Total Operating Expenses | 328.2 | 274.9 | 304.4 | 299.3 | 253.3 | 86.0 | 80.0 | 218.1 | 211.1 | 204.5 | 196.7 | 133.3 | 115.6 | 129.0 | 94.9 | 75.7 | 66.9 | |
| Operating Income | 816.3 | 816.3 | 551.5 | 337.6 | 267.5 | 275.9 | 144.3 | -67.6 | -69.3 | 81.0 | -83.2 | -27.5 | -63.0 | -80.4 | -53.6 | -19.8 | -54.3 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 21.3 | 17.3 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 37.6 | 35.3 | ||
| Depreciation & Amortization | 26.7 | 61.4 | 20.5 | 20.4 | 20.4 | 20.4 | 20.4 | 20.2 | 20.7 | 23.0 | ||
| Total Operating Expenses | 95.2 | 81.1 | 76.9 | 74.9 | 80.5 | 77.5 | 56.7 | 54.2 | 76.7 | 72.9 | ||
| Operating Income | 254.4 | 217.9 | 202.4 | 141.5 | 175.5 | 163.2 | 117.2 | 95.5 | 101.0 | 88.3 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | |
| Interest Expense | 18.1 | 18.1 | 18.1 | 18.8 | 16.9 | 7.5 | 20.4 | 11.6 | 18.0 | 22.0 | 20.0 | 5.2 | 5.6 | 3.3 | 0.0 | 0.0 | 0.0 | |
| Other Expense | -349.4 | -349.4 | 5.7 | 10.8 | -18.6 | -27.4 | -15.0 | -4.6 | 7.6 | 2.6 | 1.3 | 0.4 | 0.2 | 0.2 | 0.0 | 0.0 | 1.0 | |
| IBT | 466.9 | 466.9 | 557.1 | 348.3 | 248.9 | 248.5 | 129.3 | -72.3 | -79.8 | 61.6 | -101.9 | -32.2 | -68.4 | -83.5 | -53.6 | -19,769.9 | -53.2 | |
| Income Tax Expense | 150.0 | 150.0 | 113.0 | 66.7 | 46.8 | -154.2 | 0.2 | 0.0 | 0.5 | -1.4 | 1.2 | 3.5 | 3.8 | 2.0 | -1.1 | -1.2 | -1.0 | |
| Net Income | 316.9 | 316.9 | 444.1 | 281.6 | 202.1 | 402.7 | 129.1 | -72.2 | -80.3 | 63.0 | -103.0 | -32.2 | -68.4 | -83.5 | -53.6 | -19.8 | -53.2 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.5 | ||
| Interest Expense | 4.9 | 4.3 | 4.4 | 4.5 | 4.5 | 4.5 | 4.5 | 4.5 | 5.2 | 4.5 | ||
| Other Expense | -355.2 | 1.0 | 2.5 | 2.3 | 2.7 | 2.0 | 0.5 | 0.5 | 0.1 | 13.5 | ||
| IBT | -100.8 | 219.0 | 204.9 | 143.8 | 178.2 | 165.1 | 117.7 | 96.0 | 101.2 | 101.8 | ||
| Income Tax Expense | 40.7 | 43.7 | 39.8 | 25.7 | 41.2 | 28.1 | 24.5 | 19.2 | 15.8 | 19.9 | ||
| Net Income | -141.6 | 175.2 | 165.2 | 118.1 | 137.0 | 137.0 | 93.2 | 76.8 | 85.4 | 81.8 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $2.13 | $1.48 | $2.86 | $0.95 | $-0.50 | $-0.56 | $0.46 | $-0.81 | $-0.25 | $-0.56 | $-0.74 | $-0.48 | $-0.19 | $-0.56 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $2.10 | $1.44 | $2.74 | $0.91 | $-0.50 | $-0.56 | $0.45 | $-0.81 | $-0.25 | $-0.56 | $-0.74 | $-0.48 | $-0.19 | $-0.56 | |
| Shares Outstanding | 117.7 | 119.8 | 126.8 | 131.9 | 136.8 | 140.6 | 136.2 | 144.3 | 143.6 | 136.4 | 128.0 | 126.7 | 122.7 | 112.8 | 111.1 | 102.6 | 94.4 | |
| Diluted Shares Outstanding | 117.7 | 123.9 | 129.4 | 134.2 | 140.6 | 146.8 | 141.5 | 144.3 | 143.6 | 139.1 | 128.0 | 126.7 | 122.7 | 112.8 | 111.1 | 102.6 | 94.4 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.66 | $0.62 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.65 | $0.61 | ||
| Shares Outstanding | 117.7 | 117.2 | 121.3 | 123.2 | 126.4 | 126.9 | 127.1 | 126.9 | 129.1 | 132.0 | ||
| Diluted Shares Outstanding | 117.7 | 122.3 | 124.2 | 126.6 | 129.4 | 130.1 | 129.2 | 128.9 | 131.0 | 134.1 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 187.9 | 115.9 | 118.4 | 234.2 | 118.7 | 147.7 | 120.2 | 57.9 | 168.7 | 66.8 | 43.3 | 61.4 | 27.4 | 99.9 | 52.8 | 83.3 | |
| Short Term Investments | 341.2 | 480.2 | 217.6 | 128.6 | 622.2 | 220.3 | 301.1 | 296.6 | 300.5 | 138.2 | 65.0 | 74.2 | 44.1 | 0.0 | 0.0 | 0.0 | |
| Total Cash & ST Investments | 529.0 | 596.1 | 336.0 | 362.8 | 740.9 | 368.0 | 421.3 | 354.5 | 469.2 | 205.0 | 108.3 | 135.6 | 71.5 | 99.9 | 52.8 | 83.3 | |
| Accounts Receivable | 214.5 | 308.5 | 234.2 | 231.1 | 91.0 | 97.7 | 59.4 | 30.0 | 22.1 | 15.7 | 32.4 | 9.1 | 9.1 | 15.7 | 2.3 | 2.3 | |
| Inventory | 159.3 | 141.9 | 127.6 | 100.1 | 53.9 | 60.7 | 29.4 | 22.6 | 5.1 | 14.6 | 9.5 | 6.4 | 6.2 | 2.7 | 0.6 | 0.2 | |
| Other Current Assets | 84.9 | 39.0 | 48.6 | 45.0 | 40.5 | 28.3 | 33.4 | 20.7 | 13.9 | 21.2 | 21.5 | 10.1 | 8.4 | 12.8 | 8.3 | 3.7 | |
| Total Current Assets | 987.8 | 1,085.3 | 746.4 | 739.0 | 926.3 | 554.8 | 543.4 | 427.8 | 510.4 | 256.5 | 171.8 | 161.3 | 95.2 | 131.0 | 64.0 | 89.5 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 419.7 | 61.9 | 176.3 | 115.9 | 154.3 | 187.9 | 164.6 | 118.4 | 274.2 | 221.2 | |
| Short Term Investments | 282.3 | 486.3 | 571.6 | 480.2 | 512.0 | 341.2 | 298.8 | 217.6 | 209.1 | 127.1 | |
| Total Cash & ST Investments | 702.0 | 548.2 | 747.9 | 596.1 | 666.3 | 529.0 | 463.5 | 336.0 | 483.3 | 348.3 | |
| Accounts Receivable | 346.0 | 316.3 | 304.6 | 308.5 | 285.7 | 214.5 | 195.9 | 234.2 | 217.3 | 246.2 | |
| Inventory | 185.8 | 181.5 | 164.9 | 141.9 | 131.4 | 159.3 | 168.5 | 127.6 | 128.9 | 132.4 | |
| Other Current Assets | 95.0 | 76.7 | 44.6 | 39.0 | 43.5 | 84.9 | 45.7 | 48.6 | 49.5 | 38.9 | |
| Total Current Assets | 1,328.7 | 1,122.7 | 1,262.0 | 1,085.3 | 1,127.0 | 987.8 | 873.6 | 746.4 | 879.0 | 765.7 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 75.0 | 75.0 | 74.9 | 75.6 | 8.8 | 10.6 | 10.9 | 7.5 | 3.5 | 4.3 | 3.9 | 3.0 | 3.4 | 3.7 | 1.8 | 1.8 | |
| Goodwill | 416.8 | 416.8 | 416.8 | 409.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 437.4 | 401.8 | 472.9 | 546.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 52.3 | 80.6 | 17.8 | 26.8 | 13.9 | 14.6 | 11.6 | 4.9 | 6.1 | 0.7 | 6.1 | 1.7 | 3.2 | 0.0 | 0.0 | 0.0 | |
| Total Long-Term Assets | 981.7 | 978.1 | 986.8 | 1,102.5 | 178.1 | 25.2 | 22.4 | 12.4 | 9.6 | 5.0 | 10.0 | 4.7 | 6.6 | 3.7 | 1.8 | 1.8 | |
| Total Assets | 1,969.5 | 2,063.5 | 1,733.3 | 1,841.5 | 1,104.4 | 579.9 | 565.9 | 440.2 | 519.9 | 261.5 | 181.8 | 166.0 | 101.8 | 134.7 | 65.8 | 91.3 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 71.4 | 71.5 | 72.8 | 75.0 | 74.5 | 75.0 | 78.1 | 74.9 | 74.7 | 74.6 | |
| Goodwill | 416.8 | 416.8 | 416.8 | 416.8 | 416.8 | 416.8 | 416.8 | 416.8 | 416.8 | 416.8 | |
| Intangible Assets | 348.5 | 366.3 | 384.1 | 401.8 | 419.6 | 437.4 | 455.1 | 472.9 | 490.6 | 511.0 | |
| Long-Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 55.7 | 56.4 | 55.6 | 80.6 | 80.2 | 52.5 | 17.3 | 17.8 | 18.1 | 18.4 | |
| Total Long-Term Assets | 892.5 | 931.2 | 934.5 | 978.1 | 991.1 | 981.7 | 967.9 | 986.8 | 1,013.7 | 1,044.7 | |
| Total Assets | 2,221.2 | 2,053.9 | 2,196.5 | 2,063.5 | 2,118.0 | 1,969.5 | 1,841.5 | 1,733.3 | 1,892.7 | 1,810.4 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 15.4 | 10.2 | 11.8 | 17.7 | 1.5 | 1.9 | 6.4 | 4.1 | 7.9 | 3.6 | 4.5 | 3.0 | 3.1 | 2.3 | 7.6 | 3.8 | |
| Short-Term Debt | 30.7 | 0.0 | 0.0 | 13.3 | 89.4 | 397.2 | 19.5 | 91.5 | 77.2 | 17.4 | 21.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Liabilities | 58.0 | 128.9 | 99.7 | 96.5 | 24.4 | 20.5 | 55.6 | 49.5 | 39.6 | 28.8 | 26.8 | 14.0 | 14.9 | 7.8 | 5.6 | 8.6 | |
| Current Liabilities | 133.4 | 139.1 | 112.5 | 130.8 | 117.1 | 421.4 | 85.6 | 149.4 | 131.3 | 54.6 | 62.5 | 24.3 | 25.5 | 18.9 | 17.3 | 15.3 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 15.4 | 18.7 | 20.1 | 10.2 | 12.4 | 15.4 | 13.3 | 11.8 | 19.3 | 10.1 | |
| Short-Term Debt | 710.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Liabilities | 111.2 | 115.6 | 130.3 | 128.9 | 96.4 | 88.7 | 99.2 | 99.7 | 77.2 | 97.5 | |
| Current Liabilities | 837.2 | 134.3 | 150.4 | 139.1 | 108.8 | 133.4 | 131.6 | 112.5 | 115.2 | 116.4 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 1,502.5 | 1,505.8 | 1,499.2 | 1,492.8 | 787.3 | 0.0 | 383.0 | 34.9 | 125.1 | 199.2 | 28.0 | 49.9 | 49.8 | 31.1 | 0.0 | 0.0 | |
| Capital Leases | 30.7 | 0.0 | 32.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.5 | 0.0 | 0.0 | |
| Def. Tax Liability | 13.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | -1.5 | 0.0 | 0.0 | |
| Total Liabilities | 1,680.0 | 1,699.7 | 1,649.5 | 1,671.7 | 907.5 | 428.9 | 474.1 | 191.4 | 311.6 | 294.0 | 138.8 | 124.6 | 121.8 | 85.9 | 54.9 | 71.0 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 800.1 | 1,509.1 | 1,507.4 | 1,505.8 | 1,504.2 | 1,502.5 | 1,500.9 | 1,524.9 | 1,526.0 | 1,526.9 | |
| Capital Leases | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 30.7 | 31.8 | 32.2 | 32.4 | 33.6 | |
| Def. Tax Liability | 8.2 | 0.0 | 0.0 | 0.0 | 12.0 | 13.6 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 1,717.3 | 1,721.2 | 1,714.3 | 1,699.7 | 1,665.3 | 1,680.0 | 1,663.7 | 1,649.5 | 1,643.5 | 1,659.4 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Retained Earnings | 260.6 | 359.9 | 90.6 | 143.2 | -58.9 | -474.6 | -603.7 | -531.4 | -522.4 | -585.3 | -482.7 | -450.4 | -382.1 | -298.6 | -245.0 | -225.3 | |
| Comprehensive Income | -2.1 | 3.8 | -9.3 | -0.9 | -0.6 | 0.0 | 0.2 | -0.3 | -0.5 | 0.0 | -0.1 | 0.0 | 0.0 | -6.7 | -5.7 | -4.7 | |
| Total Common Equity | 289.4 | 363.8 | 83.8 | 169.8 | 197.0 | 151.0 | 91.8 | 248.9 | 208.4 | -32.5 | 43.0 | 41.4 | -20.0 | 48.9 | 10.9 | 20.4 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Retained Earnings | 502.1 | 361.0 | 478.0 | 359.9 | 397.6 | 260.6 | 167.4 | 90.6 | 222.3 | 140.4 | |
| Comprehensive Income | -22.3 | -28.4 | -3.4 | 3.8 | -6.9 | -2.1 | -1.5 | -9.3 | 1.2 | -1.6 | |
| Total Common Equity | 503.9 | 332.7 | 482.3 | 363.8 | 452.7 | 289.4 | 177.8 | 83.8 | 249.2 | 151.0 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 1,533.2 | 1,505.8 | 1,499.2 | 1,506.1 | 876.7 | 397.2 | 402.6 | 126.4 | 202.4 | 216.6 | 49.8 | 49.9 | 49.8 | 31.1 | 0.0 | 0.0 | |
| Book Value | 289.4 | 363.8 | 83.8 | 169.8 | 197.0 | 151.0 | 91.8 | 248.9 | 208.4 | -32.5 | 43.0 | 41.4 | -20.0 | 48.9 | 10.9 | 20.4 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 503.9 | 332.7 | 482.3 | 363.8 | 452.7 | 289.4 | 177.8 | 83.8 | 249.2 | 151.0 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 337.3 | 316.9 | 444.1 | 281.6 | 202.1 | 402.7 | 129.1 | -72.2 | -80.3 | 63.0 | -103.0 | -32.2 | -68.4 | -83.5 | -53.6 | -19.8 | -53.2 | |
| Depreciation & Amortization | 84.3 | 88.1 | 88.7 | 84.9 | 49.6 | 3.0 | 3.3 | 4.1 | 2.4 | 2.2 | 2.4 | 1.7 | 1.8 | 1.2 | 1.1 | 1.1 | 1.5 | |
| Stock-Based Compensation | 38.4 | 51.6 | 43.4 | 36.6 | 24.4 | 20.8 | 17.2 | 34.8 | 35.7 | 30.7 | 25.6 | 20.8 | 15.3 | 9.5 | 8.3 | 5.6 | 4.9 | |
| Change Working Capital | -64.7 | -152.3 | -136.3 | -38.7 | -86.0 | 3.7 | -108.4 | -50.5 | -5.9 | 20.7 | 17.0 | -29.5 | 0.1 | 22.1 | -20.2 | -21.2 | 1.5 | |
| Change In Accounts Receivable | 31.7 | -128.1 | -74.2 | -3.3 | -83.9 | 6.8 | -38.3 | -29.4 | 11.6 | -6.5 | 16.7 | -23.3 | -0.1 | 6.6 | -13.4 | 0.1 | 1.9 | |
| Change In Accounts Payable | 30.1 | 0.0 | 0.0 | -12.5 | 24.5 | 1.2 | -41.2 | 4.6 | -278.5 | 15.6 | -0.2 | 13.9 | -0.8 | 7,888.5 | -3,263.5 | 711.8 | 3.4 | |
| Change In Inventories | -56.5 | 2.6 | -67.4 | -26.9 | -17.5 | 7.4 | -31.4 | -6.7 | -17.5 | 9.5 | -5.1 | -3.1 | -0.2 | -3.5 | -2.1 | -0.4 | 1.0 | |
| Other Non-cash Items | 132.5 | 346.7 | 39.2 | -10.3 | 9.9 | 24.6 | 13.6 | -2.0 | 1.7 | 17.8 | 7.1 | 1.2 | 2.0 | 0.2 | 0.0 | 0.0 | 0.0 | |
| Cash from Operations | 420.0 | 0.0 | 0.0 | 388.6 | 240.1 | 299.4 | 55.5 | -85.4 | -49.5 | 134.1 | -50.4 | -37.1 | -47.5 | -49.3 | -64.3 | -34.4 | -45.4 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -141.6 | 175.2 | 165.2 | 118.1 | 137.0 | 137.0 | 93.2 | 76.8 | 85.4 | 81.8 | |
| Depreciation & Amortization | 26.7 | 22.3 | 22.4 | 20.4 | 22.3 | 20.4 | 22.2 | 22.0 | 20.7 | 23.1 | |
| Stock-Based Compensation | 0.0 | 12.2 | 12.2 | 10.7 | 11.5 | 12.6 | 9.5 | 9.9 | 9.7 | 9.4 | |
| Change Working Capital | -9.4 | -51.1 | -62.3 | 7.5 | -24.8 | -53.9 | -83.6 | 2.9 | -26.1 | 22.1 | |
| Change In Accounts Receivable | -90.5 | -29.7 | -11.7 | 3.8 | -22.7 | -71.2 | -18.6 | 38.3 | -16.9 | 28.9 | |
| Change In Accounts Payable | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -21.9 | 0.0 | 0.0 | 11.5 | 0.0 | |
| Change In Inventories | 18.8 | -1.1 | -14.5 | -0.6 | -7.7 | 2.0 | -21.4 | -40.2 | 1.5 | 3.6 | |
| Other Non-cash Items | 360.1 | 20.1 | -37.6 | 0.4 | 32.6 | -0.9 | 14.5 | 17.8 | 3.3 | -13.7 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 102.4 | 132.4 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -11.7 | -7.0 | -10.7 | -15.3 | -4.8 | -1.5 | -2.5 | -4.0 | -4.7 | -1.4 | -3.1 | -2.4 | -1.4 | -2.3 | -1.4 | -0.8 | -0.6 | |
| Acquisitions | 86.2 | -726.0 | 0.0 | 0.0 | -999.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | -475.2 | -247.4 | 0.0 | -292.9 | -255.2 | -652.5 | -226.2 | -389.8 | -311.1 | -398.2 | -155.4 | -71.5 | -88.9 | -48.9 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 270.4 | 722.2 | 0.0 | 211.3 | 746.1 | 247.7 | 306.0 | 388.3 | 318.3 | 235.8 | 81.8 | 79.7 | 57.3 | 3.4 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | -204.8 | 0.0 | 0.0 | 0.0 | 26.0 | 0.0 | 1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Cash from Investing | -216.5 | 0.0 | 0.0 | -96.9 | -487.0 | -406.3 | 78.4 | -5.5 | 2.5 | -163.7 | -76.8 | 5.9 | -33.0 | -47.9 | -1.4 | -0.8 | -0.6 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -1.4 | -3.0 | -1.6 | -1.0 | -3.1 | -1.5 | -2.6 | -3.5 | -2.6 | -2.9 | |
| Acquisitions | -1,013.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.7 | 80.5 | |
| Investments | 0.0 | 0.0 | 0.0 | -139.6 | 0.0 | -304.0 | 0.0 | 0.0 | -21.3 | -161.7 | |
| Sales of Investment | 273.4 | 0.0 | 0.0 | 50.2 | 0.0 | 138.0 | 0.0 | 0.0 | 15.6 | 81.2 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -5.7 | -80.5 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -8.3 | -83.5 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -13.5 | 0.0 | 0.0 | -13.5 | -447.5 | -369.1 | -19.6 | -108.1 | -77.5 | -16.0 | -54.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 50.7 | 1,505.8 | 6.6 | 6.6 | 1,076.9 | 848.5 | 14.2 | 384.3 | 1.5 | 1.7 | 221.0 | 0.0 | 0.1 | 18.7 | 31.1 | 0.0 | 0.0 | |
| Issuance of Common Stock | 15.0 | 0.0 | 0.0 | 7.9 | 14.1 | 12.5 | 63.4 | 14.2 | 13.7 | 134.9 | 1.9 | 13.1 | 107.7 | 5,079.0 | 81.5 | 0.0 | 60.0 | |
| Repurchase of Common Stock | -252.8 | -342.4 | -250.0 | -402.4 | -200.0 | -350.1 | -150.1 | -200.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | -13.5 | 0.0 | 0.0 | 0.0 | 0.0 | -12.5 | -63.4 | -14.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 6.5 | 0.0 | 0.0 | 7.9 | 995.8 | 797.0 | 63.4 | 461.3 | 0.0 | 12.8 | 203.0 | 0.0 | 6.8 | -5,054.0 | 31.3 | 4.7 | 1.9 | |
| Cash from Financing | -236.8 | 0.0 | 0.0 | -408.0 | 362.4 | 77.9 | -106.3 | 153.2 | -63.8 | 131.7 | 150.6 | 13.1 | 114.5 | 25.1 | 112.8 | 4.7 | 61.8 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 1,510.8 | 1.7 | 1.7 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.1 | |
| Repurchase of Common Stock | 0.0 | -38.9 | -300.2 | 0.0 | -250.0 | 0.0 | 0.0 | -0.5 | -252.3 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -13.5 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.4 | 4.1 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -249.9 | 4.1 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -33.3 | 20.6 | -2.5 | -116.3 | 115.5 | -29.0 | 27.5 | 62.2 | -110.8 | 102.0 | 23.5 | -18.1 | 34.0 | -72.1 | 47.1 | -30.4 | 15.8 | |
| Closing Cash Balance | 187.9 | 136.4 | 115.9 | 118.4 | 234.7 | 119.2 | 148.2 | 120.7 | 58.4 | 169.2 | 66.8 | 43.3 | 61.4 | 27.4 | 99.9 | 52.8 | 83.3 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -285.8 | 357.8 | -114.5 | 60.5 | -38.5 | -33.5 | 23.2 | 46.3 | -155.9 | 53.1 | |
| Closing Cash Balance | 133.8 | 419.7 | 61.9 | 176.3 | 115.9 | 154.3 | 187.9 | 164.6 | 118.4 | 274.2 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 408.3 | 644.6 | 468.4 | 373.3 | 235.3 | 298.0 | 53.0 | -89.5 | -54.2 | 132.7 | -53.5 | -39.4 | -48.9 | -51.6 | -65.7 | -35.2 | -46.0 | |
| Real Free Cash Flow | 369.9 | 593.0 | 425.0 | 336.7 | 210.9 | 277.2 | 35.7 | -124.2 | -89.9 | 102.0 | -79.1 | -60.3 | -64.2 | -61.2 | -74.1 | -40.7 | -50.9 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 217.6 | 175.6 | 98.1 | 153.3 | 175.4 | 113.9 | 53.2 | 125.9 | 99.8 | 129.5 | |
| Real Free Cash Flow | 217.6 | 163.4 | 86.0 | 142.6 | 164.0 | 101.3 | 43.7 | 116.0 | 90.1 | 120.1 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 23.6 | -5.6 | -1.4 |
| P/S | 5.3 | 21.1 | 9.4 |
| P/B | 14.8 | 14.6 | 5.2 |
| P/FCF | 12.2 | -5.4 | -1.5 |
| Market cap | $8.1 | $5.6 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 0 % | 46.6 % | 0 % |
| Debt to Income | 476.7 % | 93.7 % | 0 % |
| Debt to Free cash flow | 247.8 % | -31.6 % | 0 % |
| Interest expense percentage | 2.2 % | -3.5 % | 0 % |
| Current ratio | 1.6 | 5.8 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 62.9 % | 38.9 % | 0 % |
| ROA | 14.3 % | -13.1 % | 0 % |
| CapEx to Revenue | 0.5 % | 1.8 % | 0 % |
| RaD to Revenue | 0 % | 92.3 % | 0 % |
| ROEM | 3,990,317.1 | 877558.9 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 81.9 % | 84.5 % | 0 % |
| Operating margin | 58.4 % | -46.6 % | 0 % |
| Net margin | 22.7 % | -50.5 % | 0 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 1.7 % | 0 % |
| Dividend payout percentage | 0 % | 24.8 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 117.7 mil | 127.7 mil |
| Employee count | 0.4 tis | 0.2 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
